L3VLUP
ProSign in

FATE · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

FATEARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • FATE
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterFATEARGX
Q3 20208 holders, $446m8 holders, $3.6bn
Q4 202011 holders, $2.0bn7 holders, $4.1bn
Q1 202110 holders, $2.1bn8 holders, $4.1bn
Q2 202111 holders, $2.1bn9 holders, $4.6bn
Q3 20219 holders, $1.3bn8 holders, $4.5bn
Q4 20217 holders, $971m9 holders, $5.3bn
Q1 20227 holders, $677m8 holders, $5.3bn
Q2 20226 holders, $520m13 holders, $6.5bn
Q3 20227 holders, $494m14 holders, $5.3bn
Q4 20225 holders, $116m13 holders, $5.5bn
Q1 20232 holders, $483k13 holders, $5.9bn
Q2 20232 holders, $4.5m18 holders, $6.6bn
Q3 20233 holders, $4.9m21 holders, $8.7bn
Q4 20232 holders, $10.0m17 holders, $6.3bn
Q1 20245 holders, $51m13 holders, $6.8bn
Q2 20243 holders, $10m14 holders, $7.9bn
Q3 20243 holders, $17m13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 20251 holders, $6.2m17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 2026none listed holders, n.a.14 holders, $15.0bn
FATE

Fate Therapeutics Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
16
Reported value
$13.8bn
Buyers
10
Sellers
7

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 16 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only FATE (0)

None.

Only ARGX (16)

Acadian Asset Management LLC, Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Millennium Management LLC, Moore Capital Management LP, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →